# Assessment of Homologous Recombination System Gene Expression in Chemologically Induced Carcinogenesis In Vivo Models

**Authors:** Matvey M. Tsyganov, Danna Zh. Bulatova, Anastasia A. Fedorenko, Dmitry M. Loos, Pavel E. Nikiforov, Irina A. Tsydenova, Aigerim A. Bayanbayeva, Zhansaya Sharipkhanova, Sofia S. Timoshenko, Marina K. Ibragimova

PMC · DOI: 10.3390/cimb48030275 · 2026-03-04

## TL;DR

This study examines how chemical carcinogens affect DNA repair genes in mice, showing that reduced expression of these genes may contribute to tumor development.

## Contribution

The study provides new insights into how chemical carcinogens influence homologous recombination gene expression during tumor progression in vivo.

## Key findings

- Tumor formation in mice was associated with a 60% frequency of Brca1 deletions.
- Fourteen genes, including Brca1 and Rad50, showed hypoexpression in tumor tissue compared to normal tissue.
- Increased tumor mass correlated with higher frequencies of suppressed homologous recombination genes.

## Abstract

Understanding the molecular mechanisms of carcinogenesis, including disruptions in the homologous recombination system, is fundamental to understanding malignant transformation. Dysfunction of homologous recombination genes, such as BRCA1 and BRCA2, contributes to genomic instability and the development of more aggressive tumor clones. The use of chemical carcinogens enables the modeling of tumor formation and the monitoring of changes in molecular genetic parameters. This approach is important for understanding how tumor cells adapt to genotoxic stress and for advancing the development of personalized cancer therapies. The objective of this study was to evaluate the expression of key homologous recombination system genes in a model of chemically induced carcinogenesis in mice. Materials and Methods: Male outbred ICR (CD-1) laboratory mice (n = 40) were used to study chemically induced carcinogenesis. The animals were divided into four groups: two control groups and two experimental groups, which received 3-methylcholanthrene (MC) or trichloroacetic acid (TCA). Tumor cells were identified by histological analysis of autopsy material using light microscopy after standard hematoxylin and eosin staining. RNA and DNA were extracted from cell suspensions using the RNeasy Plus Mini Kit and QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), respectively. The expression levels of homologous recombination genes were assessed by RT-PCR and microarray analysis. Digital PCR was performed to assess chromosomal aberrations in the Brca1 gene. Results: Tumor formations were identified in laboratory animals two months after 3-methylcholanthrene. Histological analysis revealed morphological changes in a pleomorphic cell tumor, forming diverse, multidirectional fascicular and swirling structures, as well as large solid foci composed of markedly polymorphic spindle-shaped and epithelioid cells. Analysis of copy number aberrations in the examined samples showed that the frequency of Brca1 deletions was 60%, while 40% of animals had normal gene copy number. To further characterize the molecular changes, we assessed gene expression levels through expression microarray analysis. A total of 14 genes were hypoexpressed in the tumor compared to the normal tissue, with p < 0.05. A high level of differential expression was characteristic for Rad50, Rad51, Brca1, Brca2, and Pold4. Two genes, Rad52 and Bard1, exhibited increased expression levels. It was shown that as the tumor mass increased, so did the frequency of homologous recombination genes with hypoexpression. Conclusions: Our findings confirm that MC and TCA influence tumor formation and reveal that suppression of homologous recombination genes may contribute to this process. In addition, it has been established that as tumors progress, the expression of DNA repair genes declines and aberrant gene states accumulate. These data emphasize the importance of studying the state of DNA repair genes for the development of more effective strategies for cancer diagnosis and therapy.

## Linked entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111], RAD51 (RAD51 recombinase) [NCBI Gene 5888], BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], POLD4 (DNA polymerase delta 4, accessory subunit) [NCBI Gene 57804], RAD52 (RAD52 DNA repair protein) [NCBI Gene 5893], BARD1 (BRCA1 associated RING domain 1) [NCBI Gene 580]
- **Chemicals:** 3-methylcholanthrene (PubChem CID 1674), trichloroacetic acid (PubChem CID 6421)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Rad51 (RAD51 recombinase) [NCBI Gene 19361] {aka Rad51a, Reca}, Rad51c (RAD51 paralog C) [NCBI Gene 114714] {aka R51H3, Rad51l2}, Bard1 (BRCA1 associated RING domain 1) [NCBI Gene 12021], Topbp1 (topoisomerase (DNA) II binding protein 1) [NCBI Gene 235559] {aka 1110031N14Rik, 2810429C13Rik, D430026L04Rik, mKIAA0259}, Brip1 (BRCA1 interacting protein C-terminal helicase 1) [NCBI Gene 237911] {aka 3110009N10Rik, 8030460J03Rik, Bach1, FACJ, Fancj, OF}, Lcp1 (lymphocyte cytosolic protein 1) [NCBI Gene 18826] {aka D14Ertd310e, LCP-1, Pls2, pp65}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, Igf2 (insulin-like growth factor 2) [NCBI Gene 16002] {aka Igf-2, Igf-II, M6pr, Mpr, Peg2}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Jag1 (jagged 1) [NCBI Gene 16449] {aka ABE2, Gena228, Gsfabe2, Htu, Ozz, Ser-1}, Adamts1 (ADAM metallopeptidase with thrombospondin type 1 motif 1) [NCBI Gene 11504] {aka ADAM-TS1, ADAMTS, ADAMTS-1, C3-C5, METH-1, METH1}, Ap3b1 (adaptor-related protein complex 3, beta 1 subunit) [NCBI Gene 11774] {aka AP-3, Hps2, beta3A, pe, pearl, rim2}, Rad52 (RAD52 homolog, DNA repair protein) [NCBI Gene 19365] {aka Rad52yh}, Rad54b (RAD54 homolog B (S. cerevisiae)) [NCBI Gene 623474] {aka E130016E03Rik}, Fanci (Fanconi anemia, complementation group I) [NCBI Gene 208836], Brca1 (breast cancer 1, early onset) [NCBI Gene 12189], Pold2 (polymerase (DNA directed), delta 2, regulatory subunit) [NCBI Gene 18972] {aka 50kDa, p50, po1D2}, Casp9 (caspase 9) [NCBI Gene 12371] {aka APAF-3, CASP-9, Caspase-9, ICE-LAP6, Mch6}, Prss37 (serine protease 37) [NCBI Gene 67690] {aka 1700016G05Rik, Tryx2}, Drc11 (dynein regulatory complex subunit 11) [NCBI Gene 74918] {aka 4930465P12Rik, 4930585L22Rik, Iqca, Iqca1}, Rad51d (RAD51 paralog D) [NCBI Gene 19364] {aka R51H3, Rad51l3, TRAD, Trad-d5}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, Rad51b (RAD51 paralog B) [NCBI Gene 19363] {aka R51H2, Rad51l1, mREC2}, Palb2 (partner and localizer of BRCA2) [NCBI Gene 233826], Cdk2 (cyclin dependent kinase 2) [NCBI Gene 12566] {aka A630093N05Rik}, Chek2 (checkpoint kinase 2) [NCBI Gene 50883] {aka CHK2, Cds1, HUCDS1, Rad53}, Rad50 (RAD50 double strand break repair protein) [NCBI Gene 19360] {aka Mrell, Rad50l}, Ahr (aryl-hydrocarbon receptor) [NCBI Gene 11622] {aka Ah, Ahh, Ahre, In, bHLHe76}, Il1rn (interleukin 1 receptor antagonist) [NCBI Gene 16181] {aka F630041P17Rik, IL-1ra}, Rpa1 (replication protein A1) [NCBI Gene 68275] {aka 5031405K23Rik, 70kDa, RF-A, RP-A, Rpa}, Chek1 (checkpoint kinase 1) [NCBI Gene 12649] {aka Chk1, rad27}, Rad54l (RAD54 like (S. cerevisiae)) [NCBI Gene 19366] {aka RAD54}, Pold4 (polymerase (DNA-directed), delta 4) [NCBI Gene 69745] {aka 2410012M21Rik, Polds, p12}, Bmp6 (bone morphogenetic protein 6) [NCBI Gene 12161] {aka D13Wsu115e, Vgr1}, Fancl (Fanconi anemia, complementation group L) [NCBI Gene 67030] {aka 2010322C19Rik, B230118H11Rik, Phf9, Pog, gcd}, Cnn3 (calponin 3, acidic) [NCBI Gene 71994] {aka 1600014M03Rik, Calpo3}, Cdk12 (cyclin dependent kinase 12) [NCBI Gene 69131] {aka 1810022J16Rik, Crk7, Crkrs, D11Ertd752e, Pksc}, Pold3 (polymerase (DNA-directed), delta 3, accessory subunit) [NCBI Gene 67967] {aka 2410142G14Rik, P66, P68}, Vgll1 (vestigial like family member 1) [NCBI Gene 170828] {aka Tondu}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Mre11a (MRE11A homolog A, double strand break repair nuclease) [NCBI Gene 17535] {aka Mre11, Mre11b}, Nbn (nibrin) [NCBI Gene 27354] {aka Nbs1}, Ppp2r2a (protein phosphatase 2, regulatory subunit B, alpha) [NCBI Gene 71978] {aka 2410004D02Rik, B55, mKIAA1541}, Zranb3 (zinc finger, RAN-binding domain containing 3) [NCBI Gene 226409] {aka 4933425L19Rik, AH2, C730006D09}, Pold1 (polymerase (DNA directed), delta 1, catalytic subunit) [NCBI Gene 18971] {aka 125kDa}, Fancd2 (Fanconi anemia, complementation group D2) [NCBI Gene 211651] {aka 2410150O07Rik, FA-D2, FA4, FACD, FAD, FANCD}, Myb (Myb proto-oncogene, transcription factor) [NCBI Gene 17863] {aka c-myb}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Atm (ataxia telangiectasia mutated) [NCBI Gene 11920] {aka C030026E19Rik}, Sp1 (trans-acting transcription factor 1) [NCBI Gene 20683] {aka 1110003E12Rik, Sp1-1}, Ddb2 (damage specific DNA binding protein 2) [NCBI Gene 107986] {aka 2610043A19Rik}, Cyp1a1 (cytochrome P450, family 1, subfamily a, polypeptide 1) [NCBI Gene 13076] {aka AHH, AHRR, CP11, CYPIA1, P450-1}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Pole (polymerase (DNA directed), epsilon) [NCBI Gene 18973], Sycp3 (synaptonemal complex protein 3) [NCBI Gene 20962] {aka Cor1, Scp3}
- **Diseases:** liver damage (MESH:D056486), I and III malignancy (MESH:D009369), breast cancer (MESH:D001943), lymphomas (MESH:D008223), HRD (MESH:C535296), carcinogenic (MESH:D011230), hyperplasia (MESH:D006965), inflammation (MESH:D007249), injury to (MESH:D014947), hemorrhages (MESH:D006470), liver tumors (MESH:D008113), metastases (MESH:D009362), Carcinogenesis (MESH:D063646), toxicity (MESH:D064420), kidney tumors (MESH:D007680), grade II malignancy (MESH:D001254), breast carcinogenesis (MESH:D061325), basal- (MESH:D002280), oncological (MESH:D000072716)
- **Chemicals:** formalin (MESH:D005557), paraffin (MESH:D010232), FAM (MESH:C031179), olive oil (MESH:D000069463), amino acids (MESH:D000596), HCl (MESH:D006851), CO2 (MESH:D002245), Tween-20 (MESH:D011136), hematoxylin (MESH:D006416), PAH (MESH:D011084), water (MESH:D014867), RNAlater solution (-), 3-Methylcholanthrene (MESH:D008748), toluene (MESH:D014050), eosin (MESH:D004801), MgCl2 (MESH:D015636), vegetable oil (MESH:D010938), TCA (MESH:D014238), (NH4)2SO4 (MESH:D000645)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** S346X
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025133/full.md

---
Source: https://tomesphere.com/paper/PMC13025133